Key result
Artemisinin suppresses ventricular tachyarrhythmia in ~100% of ex-vivo Brugada models, recovering the action potential dome.
Why the study?
The study investigated the effect of artemisinin on suppressing electrocardiographic manifestations in a canine experimental model of BrS.
Does artemisinin suppress ventricular tachyarrhythmia and electrocardiographic manifestations in an ex-vivo canine model of Brugada Syndrome?
Does artemisinin suppress ventricular tachyarrhythmia and electrocardiographic manifestations in an ex-vivo canine model of Brugada Syndrome?
Artemisinin effectively suppresses ventricular tachyarrhythmia and restores electrophysiological parameters in an ex-vivo canine model of Brugada Syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Brugada syndrome therapy; should not change practice without human data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jeong et al. (2023) studied Brugada Syndrome (n=8). Artemisinin was evaluated on Suppression of ventricular tachyarrhythmia. Artemisinin suppressed ventricular tachyarrhythmia in all 6 induced preparations and recovered the action potential dome in all 8 canine ex-vivo Brugada syndrome models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: